An industry veteran with more than 35 years in oncology drug development and more than a decade in biomarker and drug diagnostic co-development, Dr. Steven D. Averbuch has contributed to multiple drug and companion diagnostic approvals in the U.S. and other major markets. 

​

Formerly at Bristol-Myers Squibb (BMS) he led integrated biomarker and pharmacodiagnostic activities across the company’s R&D portfolio. During his tenure, Dr. Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, established in 2008, which led to the application of BMS’ precision medicine strategy across all therapeutic areas. Under his leadership, the Center integrated the co-development and co-commercialization of diagnostic tests as companions to BMS medicines. Previously, Dr. Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine and served as the Head of Early Global Clinical Research, where he was responsible for early asset development strategy and execution of all Phase 2 oncology programs. 

​

He has served in leadership roles at Merck Research Laboratories and at AstraZeneca. He is a member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research.